| 标题： | 中国老年糖尿病诊疗指南（2024年版） |
| title： | Guideline for the management of diabetes mellitus in the elderly in China (2024 edition) |
| 版本： | 更新版 |
| version： | Updated |
| 分类： | 标准指南 |
| classification： | Standard guideline |
| 领域： | 综合 |
| field： | Comprehensive guideline |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 内分泌科医师、老年科医师、全科医师 |
| Guide users： | Endocrinologist, Geriatrician and General Practitioner |
| 证据分级方法： | 将证据级别分为A、B、C。证据级别A：证据基于多项随机对照试验或Meta分析。证据级别B：证据基 于单项随机对照试验或多项非随机对照研究。证据级别C：仅为专家共识意见和(或)基于小规模研究、回顾性研究和注册研究结果。 |
| Evidence grading method： | The evidence level is classified into A, B, and C. Evidence level A: The evidence is based on multiple randomized controlled trials or Meta-analysis. Evidence level B: The evidence is based on a single randomized controlled trial or multiple non-randomized controlled studies. Evidence level C: It is only expert consensus and/or based on small-scale studies, retrospective studies, and results from registries. |
| 制定单位： | 国家老年医学中心中华医学会老年医学分会 中国老年保健协会糖尿病专业委员会 |
| Formulating unit： | National Center of Gerontology, Chinese Society of Geriatrics, Diabetes Professional Committee of Chinese Aging Well Association |
| 注册时间： | 2023-11-19 |
| Registration time： | |
| 注册编号： | PREPARE-2023CN921 |
| Registration number： | |
| 指南制订的目的： | 随着我国老龄化的加剧以及日益增长的老年糖尿病管理需求,老年糖尿病患者的管理亟需规范，2021年我们颁布了国内第一部关于老年糖尿病管理的权威指南，阅读量及下载量均位于同期指南的前列。近3年来，老年糖尿病领域陆续涌现了新的基础和临床研究，包括新的控制糖尿病及并发症的药物的问世，老年糖尿病相关临床研究证据也进一步累积，基于此，国家老年医学中心、中华医学会老年医学分会、中国老年保健协会糖尿病专业委员会组织国内糖尿病、老年病及相关领域知名专家共同对《中国老年糖尿病诊疗指南(2021年版)》进行更新，撰写《中国老年糖尿病诊疗指南(2024年版)》，旨在指导和帮助临床医师对国内老年糖尿病患者进行全方位、全周期的规范化综合管理，改善中国老年糖尿病患者的临床结局。 |
| Purpose of the guideline： | With the intensification of aging in our country and the increasing management needs of elderly patients with diabetes, there is an urgent need to standardize the management of elderly diabetes patients. In 2021, we issued the first authoritative domestic guidelines on the management of elderly diabetes, which had high readership and download rates, ranking among the top guidelines of the same period. In the past three years, new basic and clinical research has emerged in the field of elderly diabetes, including the introduction of new drugs for controlling diabetes and its complications. The evidence from clinical studies related to elderly diabetes has accumulated. Based on this, the National Center of Gerontology, Chinese Society of Geriatrics, and Diabetes Professional Committee of Chinese Aging Well Association organized well-known domestic experts in the fields of diabetes, geriatric diseases, and related areas to jointly update the "Guideline for the management of diabetes mellitus in the elderly in China (2021 edition)" and write the "Guideline for the management of diabetes mellitus in the elderly in China (2024 edition)" with the aim of guiding and assisting clinicians in the comprehensive standardized management of elderly diabetes patients in China throughout the entire care cycle, and improving the clinical outcomes of elderly diabetes patients in China. |
最新注册
